Additionally, employing a neurology 4-plex-A biomarker panel alongside plasma α-synuclein has demonstrated potential with respect to the differentiation of PD patients from healthy individuals and with respect to the prediction of clinical disease progression [140]. Here, SNCA is linked to Parkinson disease.